Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nichi-Iko Takes Share Of Korean Biosimilar Firm, Gains Japanese Rights For Remicade And Herceptin Generics

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Nichi-Iko has upped its capability to bring biosimilars to the Japanese market, buying a 33 percent stake in South Korean biosimilar firm Aprogen, giving the Japanese generics maker exclusive rights to Aprogen products in Japan

You may also be interested in...



Biogen Tests Biosimilars Waters In Joint Venture With Samsung

A joint venture with Korean conglomerate Samsung will be limited to making generic versions of non-Biogen products, although Samsung separately is working on a biosimilar of rituximab.

Korea’s Samsung And Biogen Idec Initiate JV For Global Biosimilars Development

The $300 million Korean joint venture gives Samsung a global stage but raises questions about its Rituxan biosimilars program.

Sanofi-Aventis Scans Asian Firms For Alliances In Biosimilar Development And Marketing

SINGAPORE - European drug maker Sanofi-Aventis is scouting for Asia-centric joint ventures or collaborative arrangements to accelerate its presence in the biosimilars space. Sanofi is hoping to make up ground as some of its global peers have advanced in the segment to capitalize on some of the biggest revenue drivers expected to unfold in the next five to eight years

Related Content

UsernamePublicRestriction

Register

SC073356

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel